Back to Newsroom
Back to Newsroom

Regulus Therapeutics Soars on Hepatitis C Drug Data; Facebook Launches Chat App "Rooms"

Friday, 24 October 2014 12:00 AM

Topic:

ACCESSWIRE / October 24, 2014 / Sunday's Presidential Election help Petr (NYSE: PBR) shares slump 5.61% at the close on Thursday.

For an in-depth report on Petr follow: www.pennystocktitans.com/stockquote/PBR

PBR is down is down 19% this week and so far 12% lower for 2014. Brazil will hold its Presidential Electio on Sunday. The country's incumbent Pres. Dilma Rousseff is running again Aecio Neves, a former governor. State controlled oil company Petrobras has been volatile in share price heading into the election.

Chat room app "Rooms" pushes Facebook, Inc. (NASDAQ:FB) shares to a new 52-week high of $80.63.

For an in-depth report on Facebook, Inc. follow: www.pennystocktitans.com/stockquote/FB

Facebook has launched an anonymous chat room app called Rooms that is free and now available in the App Store. The app allows users to create chat rooms for shared interests. It is entirely separate from Facebook and doesn't require details like your name or your location. Rooms was created by Josh Miller, co-founder of the site Branch which Facebook acquired earlier this year.

PennyStockTitans wants to help everyday people gain awareness about some of the hottest stocks trading in the stock market today. PennyStockTitans.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.pennystocktitans.com/ to get full access to our free stock reports.

Hepatitis C treatment news helps Regulus Therapeutics Inc. (NASDAQ: RGLS) shares double in one trading day.

For an in-depth report on Regulus Therapeutics Inc. follow: www.pennystocktitans.com/stockquote/RGLS

Shares of RGLS more than doubled on Wednesday as early testing of a hepatitis C drug received positive feedback. Regulus is testing several doses of the drug. The company said that patients who received a single injection of its drug RG-101 still had lower viral loads four weeks later. The drug worked in patients with different viral genotypes and varying treatment histories. The stock reached an all-time high of $15.38 this week.

Agreement with GD Solar pushes Solar Power, Inc. (OTC: SOPW) to a new 52-week high of $2.89.

For an in-depth report on Solar Power, Inc. follow: www.pennystocktitans.com/stockquote/SOWP

Solar Power Inc. and Guodian Technology & Environment Group have agreed to develop at least 1.5 gigawatts of capacity in China. Solar Power will buy 160 megawatts of photovoltaic capacity from affiliates of Guodian Technology's GD Solar unit for $257 million. The companies will develop 500 megawatts each year from 2015 through 2017. Solar Power will provide financing and hold equity stakes in the projects that GD Solar will build.

Disclosure: PennyStockTitans.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

 

SOURCE: Stock Publisher

Topic:
Back to newsroom
Back to Newsroom
Share by: